Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2021 | Improving enrolment diversity in clinical trials for breast cancer

Mark Lythgoe • 26 Apr 2021
ESMO Breast 2021
Breast Cancer

Mark Lythgoe, MD, Imperial College London & Hammersmith Hospital, London, UK, discusses how diversity and inclusion of minority populations can be improved in clinical trial enrollment, in particular for patients with triple-negative breast cancer. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

More from Mark Lythgoe

2:11
Racial diversity in FDA registration trials for breast cancer
Mark Lythgoe • 26 Apr 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals